Our Latest Blog
& Researches.
- By: Dr.Aqsa Zafar
-
Comment (1)
-
27-05-2024 01:08:04am
Palbociclib: A Comprehensive Overview
Palbociclib is an innovative oral medication used in the treatment of certain types of breast cancer. It belongs to a class of drugs known as CDK4/6 inhibitors, which play a crucial role in managing hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. This medication is particularly significant for postmenopausal women whose cancer is advanced or metastatic.Read more.....
- By: Dr.Aqsa Zafar
-
08-05-2024 06:04:22am
Overview Of Procarbazine Hydrochloride: An Anti-Cancer Drug .
Procarbazine hydrochloride is a medication used in the treatment of certain types of cancer. It belongs to a class of drugs known as alkylating agents, which work by interfering with the DNA of cancer cells, ultimately inhibiting their growth and proliferation. This drug is commonly used in combination with other chemotherapy medications to effectively treat Hodgkin's lymphoma, certain types of brain tumors, and other cancers.Read more.....
- By: Dr.Aqsa Zafar
-
17-04-2024 11:08:50pm
Revolutionizing Cancer Care: Breakthroughs in Anticancer Medications
The landscape of cancer treatment has undergone a remarkable transformation in recent years, thanks to groundbreaking advancements in anticancer medications. These breakthroughs represent a significant shift in how we approach and manage various types of cancer, offering new hope and improved outcomes for patients worldwide. One of the most prominent breakthroughs in anticancer medications is the development of immune checkpoint inhibitors. These medications work by targeting specific checkpoints in the immune system that cancer cells exploit to evade detection and destruction. By blocking these checkpoints, drugs like pembrolizumab and nivolumab unleash the body's immune system, allowing it to recognize and attack cancer cells more effectively.Read more.....
- By: Dr Aqsa Zafar
-
15-02-2024 10:49:57pm
Exploring the Link Between Diabetes and Sleep: Unveiling the Impact of Sleep on Blood Sugar Levels
This insightful blog explores the intricate relationship between sleep and diabetes, emphasizing the impact of sleep on blood sugar levels. Covering topics such as circadian rhythm, insulin resistance, chronotypes, sleep disorders, hormonal dynamics, and practical tips, it provides a holistic understanding of the Diabetes-Sleep Connection. The article concludes by highlighting the crucial role of cultivating healthy sleep habits for effective diabetes management and overall well-being.Read more.....
- By: Dr Aqsa Zafar
-
2023-12-15 23:18:53
Hydrogel-Based Controlled Drug Delivery for Cancer Treatment: A Review
As an emerging drug carrier, hydrogels have been widely used for tumor drug delivery. A hydrogel drug carrier can cause less severe side effects than systemic chemotherapy and can achieve sustained delivery of a drug at tumor sites. In addition, hydrogels have excellent biocompatibility and biodegradability and lower toxicity than nanoparticle carriers. Smart hydrogels can respond to stimuli in the environment (e.g., heat, pH, light, and ultrasound), enabling in situ gelation and controlled drug release, which greatly enhance the convenience and efficiency of drug delivery.Read more.....
- By: Dr Aqsa Zafar
-
2023-12-14 23:38:27
CURRENT LANDSCAPE FROM CLINICAL TRIALS AND FUTURE OF COMBINEDCHECKPOINTS BLOCKADE IMMUNOTHERAPY IN CANCERS
Immunotherapy is among cancer immunology's fastest and most furious treatment strategies. The therapeutic perspective of checkpoint inhibitors is represented through the Food and Drug Administration (FDA) approvals for their implementation in various malignancies. Efforts to improve results with immunotherapeutic agents have led to the design of advanced treatment strategies. Current preclinical evidence estimating immune checkpoint inhibitors in several cancer cell lines has recommended that combinatorial approaches may have better survival results than monotherapy. Experimental trials evaluating combined therapy with anti-PD-1/ PD-L1 plus anti-CTLA-4 checkpoint inhibitors have reported considerable leads in survival indices over single immunotherapy. The therapeutic prospective of combinatorial approaches is focused on nivolumab with ipilimumab for advanced melanoma patients. Combined checkpoint inhibition with anti-PD-1/PDL1 plus anti-CTLA-4 monoclonal antibodies is beinRead more.....
